{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:14:30Z","timestamp":1790075670247,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03842-y","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T21:01:16Z","timestamp":1727902876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data"],"prefix":"10.1007","volume":"73","author":[{"given":"Patrick","family":"Reimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra-Antonia","family":"Mavroeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Burghofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Webersinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Morariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo Andreas","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kirchweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Djanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Benda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Doleschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"9","key":"3842_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557\u2013588","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3842_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(2):127\u2013140","journal-title":"Ann Oncol"},{"issue":"1","key":"3842_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics 2024 CA: a cancer. J Clin 74(1):12\u201349","journal-title":"J Clin"},{"issue":"3","key":"3842_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: a cancer. J Clin 74(3):229\u2013263","journal-title":"J Clin"},{"issue":"4","key":"3842_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","volume":"35","author":"C Anderson","year":"2009","unstructured":"Anderson C, Kim R (2009) Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev 35(4):322\u2013327","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"3842_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD et al (2007) Cholangiocarcinoma. Ann Surg 245(5):755\u2013762","journal-title":"Ann Surg"},{"issue":"9","key":"3842_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943\u2013962","journal-title":"Cancer Discov"},{"issue":"3","key":"3842_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000011961","volume":"56","author":"M Raderer","year":"1999","unstructured":"Raderer M, Hejna MHL, Valencak JB, Kornek GV, Weinl\u00e4nder GS, Bareck E et al (1999) Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56(3):177\u2013180","journal-title":"Oncology"},{"issue":"14","key":"3842_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"8","key":"3842_CR10","first-page":"EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM \u00c9vid 1(8):EVIDoa2200015","journal-title":"NEJM \u00c9vid"},{"issue":"6","key":"3842_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796\u2013807","journal-title":"Lancet Oncol"},{"issue":"5","key":"3842_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671\u2013684","journal-title":"Lancet Oncol"},{"issue":"9","key":"3842_CR13","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M et al (2020) Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21(9):1234\u20131243","journal-title":"Lancet Oncol"},{"issue":"9","key":"3842_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B et al (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9):1290\u20131300","journal-title":"Lancet Oncol"},{"key":"3842_CR15","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","volume":"40","author":"A Ohba","year":"2022","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S et al (2022) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol 40:4006\u20134006","journal-title":"J Clin Oncol"},{"key":"3842_CR16","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1200\/JCO.2024.42.16_suppl.4090","volume":"42","author":"DY Oh","year":"2024","unstructured":"Oh DY, Lugowska IA, Stroyakovskiy D, Jung KH, Dumas O, Penkov K et al (2024) Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). J Clin Oncol 42:4090\u20134090","journal-title":"J Clin Oncol"},{"issue":"2","key":"3842_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21(2):271\u2013282","journal-title":"Lancet Oncol"},{"key":"3842_CR18","doi-asserted-by":"publisher","first-page":"1143825","DOI":"10.3389\/fonc.2023.1143825","volume":"13","author":"H Taghizadeh","year":"2023","unstructured":"Taghizadeh H, Schmalfuss T, Maj-Hes A, Singer J, Prager GW (2023) Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients. Front Oncol 13:1143825","journal-title":"Front Oncol"},{"issue":"1","key":"3842_CR19","doi-asserted-by":"publisher","first-page":"15421","DOI":"10.1038\/s41598-023-42083-4","volume":"13","author":"B Doleschal","year":"2023","unstructured":"Doleschal B, Taghizadeh H, Webersinke G, Piringer G, Schreil G, Decker J et al (2023) Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment. Sci Rep 13(1):15421","journal-title":"Sci Rep"},{"key":"3842_CR20","doi-asserted-by":"crossref","unstructured":"Verdaguer H, Saur\u00ed T, Acosta DA, Guardiola M, Sierra A, Hernando J, et al. (2022) ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res. 28(8): clincanres.2384.2021.","DOI":"10.1158\/1078-0432.CCR-21-2384"},{"issue":"5","key":"3842_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11523-023-00985-3","volume":"18","author":"D Zhang","year":"2023","unstructured":"Zhang D, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M et al (2023) A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the comprehensive cancer center munich. Target Oncol 18(5):767\u2013776","journal-title":"Target Oncol"},{"key":"3842_CR22","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Online. 2020;91\u20132."},{"key":"3842_CR23","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Online. 2020;83\u20134."},{"key":"3842_CR24","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Online. 2020;85\u20136."},{"key":"3842_CR25","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Online. 2020;89\u201390."},{"issue":"8","key":"3842_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103630","volume":"9","author":"IA Mavroeidi","year":"2024","unstructured":"Mavroeidi IA, Burghofer J, Kalbourtzis S, Taghizadeh H, Webersinke G, Piringer G et al (2024) Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity. ESMO Open 9(8):103630","journal-title":"ESMO Open"},{"key":"3842_CR27","doi-asserted-by":"crossref","unstructured":"Belli C, Bielo LB, Repetto M, Crimini E, Scalia R, Diana A, et al. Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. Oncol. 2024;oyae125.","DOI":"10.1093\/oncolo\/oyae125"},{"issue":"19","key":"3842_CR28","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-22-1152","volume":"28","author":"NJ Chiang","year":"2022","unstructured":"Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP et al (2022) Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: a phase II T1219 study. Clin Cancer Res 28(19):4248\u20134257","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3842_CR29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"T Zeng","year":"2023","unstructured":"Zeng T, mei, Yang G, Lou C, Wei W, Tao C jie, Chen X yun, et al (2023) Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun 14(1):1340","journal-title":"Nat Commun"},{"issue":"D1","key":"3842_CR30","doi-asserted-by":"publisher","first-page":"D835","DOI":"10.1093\/nar\/gkz972","volume":"48","author":"MJ Landrum","year":"2019","unstructured":"Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J et al (2019) ClinVar: improvements to accessing data. Nucleic acids Res 48(D1):D835\u2013D844","journal-title":"Nucleic acids Res"},{"issue":"D1","key":"3842_CR31","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2023","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita MK et al (2023) COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res 52(D1):D1210\u2013D1217","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3842_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R et al (2019) VarSome: the human genomic variant search engine. Bioinformatics 35(11):1978\u20131980","journal-title":"Bioinformatics"},{"key":"3842_CR33","unstructured":"AlamutTM Visual plus version 1.6.1 [Internet]. SOPHiA GENETICSTM."},{"issue":"1","key":"3842_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41698-023-00458-w","volume":"7","author":"A Mock","year":"2023","unstructured":"Mock A, Teleanu MV, Kreutzfeldt S, Heilig CE, H\u00fcllein J, M\u00f6hrmann L et al (2023) NCT\/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. NPJ Precis Oncol 7(1):109","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"3842_CR35","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29(9):1895\u20131902","journal-title":"Ann Oncol"},{"issue":"5","key":"3842_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013423","journal-title":"Genet Med"},{"issue":"8","key":"3842_CR37","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT et al (2024) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 9(8):694\u2013704","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3842_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris","year":"2024","unstructured":"Burris HA, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25(5):626\u2013635","journal-title":"Lancet Oncol"},{"issue":"10391","key":"3842_CR39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"8","key":"3842_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T et al (2023) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int 43(8):1803\u20131812","journal-title":"Liver Int"},{"issue":"2","key":"3842_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11523-024-01032-5","volume":"19","author":"M Rimini","year":"2024","unstructured":"Rimini M, Loi E, Rizzato MD, Pressiani T, Vivaldi C, Gusmaroli E et al (2024) Different genomic clusters impact on responses in advanced biliary tract cancer treated with cisplatin plus gemcitabine plus durvalumab. Target Oncol 19(2):223\u2013235","journal-title":"Target Oncol"},{"key":"3842_CR42","doi-asserted-by":"publisher","first-page":"S1457","DOI":"10.1016\/j.annonc.2022.10.104","volume":"33","author":"JW Valle","year":"2022","unstructured":"Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee CK, Tan BJ et al (2022) 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol 33:S1457","journal-title":"Ann Oncol"},{"key":"3842_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population. Eur J cancer 208:114199","journal-title":"Eur J cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03842-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T07:04:28Z","timestamp":1731740668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03842-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03842-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4840712\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees Essen (21\u201310239-BO, Essen, Germany), Land Oberoesterreich (1100\/2023, Upper Austria, Austria), and Vienna (EK-1099\/2021, Vienna, Austria).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"251"}}